In the present study, we have used a cell model and human tissues to demonstrate that PAK1 confers cisplatin resistance in NSCLC cells via a mechanism involving the ERK/GSK3β/β-catenin cascade and β-catenin-mediated stemness. Here, PAK1 is linked to non-small cell lung carcinoma.